Aktuelle Tagungsinformationen
News and Updates
Anmeldung zur Tagung
Registration
Hotelbuchung
Hotel Registration
Grußwort
Welcome address
Beteiligte Gesellschaften
Societies involved
Eröffnung des Kongresses
Opening Ceremony
Preise
Awards
Wissenschaftliches Programm
Scientific program
Posterpräsentationen
Poster Presentation
Kurse
Courses
Begleitende Veranstaltungen
Collateral Events
Rahmenprogramm
Social program
Jubiläumsparty
Jubilee Party
DOG Information
DOG Information
Allgemeine Informationen
General Information
Autorenindex
Index of Authors
Ausstellerliste
Exhibitors
Sponsoren
Sponsors
Teilnahmegebühren
Registration fees
Impressum
DOG Homepage
Quality of Life Assessment - How to Evaluate Outcome after Therapeutic Interventions for AMD?
Rubin G. S.,
Institute of Ophthalmology (London)
Advanced age-related macular degeneration (AMD) remains the leading cause of severe visual impairment in Europe and North America. In recent years we have seen the introduction of several new therapeutic interventions for AMD including photodynamic therapy, external beam radiotherapy, nutritional supplements, and retinal translocation. It is now well recognized that visual acuity alone does not provide an adequate characterization of the potential benefits and risks of treatment. Patient-based outcomes, especially quality of life (QoL) questionnaires, have become an increasingly important part of the therapeutic evaluation process. QoL data complement other forms of patient-based outcomes assessment such as direct observation of task performance. The role of QoL assessment and the standards for selecting appropriate QoL instruments will be discussed. Particular attention will be paid to measurement issues and the interpretation of QoL outcomes.